GB201413240D0 - Method - Google Patents

Method

Info

Publication number
GB201413240D0
GB201413240D0 GBGB1413240.1A GB201413240A GB201413240D0 GB 201413240 D0 GB201413240 D0 GB 201413240D0 GB 201413240 A GB201413240 A GB 201413240A GB 201413240 D0 GB201413240 D0 GB 201413240D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1413240.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Medical AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical AB filed Critical Hansa Medical AB
Priority to GBGB1413240.1A priority Critical patent/GB201413240D0/en
Publication of GB201413240D0 publication Critical patent/GB201413240D0/en
Priority to FIEP15756845.2T priority patent/FI3171891T3/fi
Priority to PL15756845.2T priority patent/PL3171891T3/pl
Priority to HRP20251560TT priority patent/HRP20251560T1/hr
Priority to LTEPPCT/EP2015/065895T priority patent/LT3171891T/lt
Priority to NZ728265A priority patent/NZ728265B2/en
Priority to EA201790192A priority patent/EA039169B1/ru
Priority to DK15756845.2T priority patent/DK3171891T3/da
Priority to HK17105550.2A priority patent/HK1232122B/en
Priority to KR1020237026683A priority patent/KR20230119267A/ko
Priority to JP2017524097A priority patent/JP6708641B2/ja
Priority to EP25199052.9A priority patent/EP4663755A3/en
Priority to ES15756845T priority patent/ES3054696T3/es
Priority to CN202210234712.4A priority patent/CN114949187A/zh
Priority to CN201580049441.3A priority patent/CN106714834A/zh
Priority to CA2955704A priority patent/CA2955704A1/en
Priority to MYPI2017000280A priority patent/MY196858A/en
Priority to EP15756845.2A priority patent/EP3171891B1/en
Priority to IL249981A priority patent/IL249981B/en
Priority to KR1020177005456A priority patent/KR102565244B1/ko
Priority to PT157568452T priority patent/PT3171891T/pt
Priority to US15/328,879 priority patent/US10973889B2/en
Priority to MX2017001138A priority patent/MX2017001138A/es
Priority to SI201532086T priority patent/SI3171891T1/sl
Priority to BR112017001420A priority patent/BR112017001420A2/pt
Priority to SG11201700172WA priority patent/SG11201700172WA/en
Priority to RS20251260A priority patent/RS67520B1/sr
Priority to AU2015294125A priority patent/AU2015294125B2/en
Priority to PCT/EP2015/065895 priority patent/WO2016012285A2/en
Priority to CONC2017/0000571A priority patent/CO2017000571A2/es
Priority to CL2017000191A priority patent/CL2017000191A1/es
Priority to US17/191,634 priority patent/US12397044B2/en
Priority to US19/261,759 priority patent/US20260000739A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
GBGB1413240.1A 2014-07-25 2014-07-25 Method Ceased GB201413240D0 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
GBGB1413240.1A GB201413240D0 (en) 2014-07-25 2014-07-25 Method
PCT/EP2015/065895 WO2016012285A2 (en) 2014-07-25 2015-07-10 Method
MYPI2017000280A MY196858A (en) 2014-07-25 2015-07-10 Method
EP15756845.2A EP3171891B1 (en) 2014-07-25 2015-07-10 Method
HRP20251560TT HRP20251560T1 (hr) 2014-07-25 2015-07-10 Postupak
LTEPPCT/EP2015/065895T LT3171891T (lt) 2014-07-25 2015-07-10 Būdas
NZ728265A NZ728265B2 (en) 2015-07-10 Methods to enhance organ transplant and antibody therapies
EA201790192A EA039169B1 (ru) 2014-07-25 2015-07-10 СПОСОБ СНИЖЕНИЯ Fc-РЕЦЕПТОРНОГО СВЯЗЫВАНИЯ МОЛЕКУЛ СЫВОРОТОЧНОГО IgG У СУБЪЕКТА
DK15756845.2T DK3171891T3 (da) 2014-07-25 2015-07-10 Fremgangsmåde
HK17105550.2A HK1232122B (en) 2014-07-25 2015-07-10 Method
KR1020237026683A KR20230119267A (ko) 2014-07-25 2015-07-10 장기 이식 거부 방지용 약학적 조성물
JP2017524097A JP6708641B2 (ja) 2014-07-25 2015-07-10 方法
EP25199052.9A EP4663755A3 (en) 2014-07-25 2015-07-10 Method
ES15756845T ES3054696T3 (en) 2014-07-25 2015-07-10 Method
CN202210234712.4A CN114949187A (zh) 2014-07-25 2015-07-10 改善疗法或治疗剂的益处的方法
CN201580049441.3A CN106714834A (zh) 2014-07-25 2015-07-10 一种方法
CA2955704A CA2955704A1 (en) 2014-07-25 2015-07-10 Method of improving the benefit of a therapy or a therapeutic agent
FIEP15756845.2T FI3171891T3 (fi) 2014-07-25 2015-07-10 Menetelmä
KR1020177005456A KR102565244B1 (ko) 2014-07-25 2015-07-10 장기 이식 거부 방지용 약학적 조성물
PL15756845.2T PL3171891T3 (pl) 2014-07-25 2015-07-10 Sposób
IL249981A IL249981B (en) 2014-07-25 2015-07-10 Preparations that include ingredients that reduce the binding of the fc receptor to IgG molecules in the serum and their use
PT157568452T PT3171891T (pt) 2014-07-25 2015-07-10 Método
US15/328,879 US10973889B2 (en) 2014-07-25 2015-07-10 Method for improving the benefit of organ transplant
MX2017001138A MX2017001138A (es) 2014-07-25 2015-07-10 Metodo.
SI201532086T SI3171891T1 (sl) 2014-07-25 2015-07-10 Postopek
BR112017001420A BR112017001420A2 (pt) 2014-07-25 2015-07-10 método
SG11201700172WA SG11201700172WA (en) 2014-07-25 2015-07-10 Method
RS20251260A RS67520B1 (sr) 2014-07-25 2015-07-10 Postupak
AU2015294125A AU2015294125B2 (en) 2014-07-25 2015-07-10 Method
CONC2017/0000571A CO2017000571A2 (es) 2014-07-25 2017-01-24 Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena
CL2017000191A CL2017000191A1 (es) 2014-07-25 2017-01-25 Método
US17/191,634 US12397044B2 (en) 2014-07-25 2021-03-03 Method for improving the benefit to a subject of a therapy or therapeutic agent
US19/261,759 US20260000739A1 (en) 2014-07-25 2025-07-07 Method for improving the benefit to a subject of a therapy or therapeutic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1413240.1A GB201413240D0 (en) 2014-07-25 2014-07-25 Method

Publications (1)

Publication Number Publication Date
GB201413240D0 true GB201413240D0 (en) 2014-09-10

Family

ID=51587261

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1413240.1A Ceased GB201413240D0 (en) 2014-07-25 2014-07-25 Method

Country Status (26)

Country Link
US (3) US10973889B2 (enExample)
EP (2) EP3171891B1 (enExample)
JP (1) JP6708641B2 (enExample)
KR (2) KR20230119267A (enExample)
CN (2) CN106714834A (enExample)
AU (1) AU2015294125B2 (enExample)
BR (1) BR112017001420A2 (enExample)
CA (1) CA2955704A1 (enExample)
CL (1) CL2017000191A1 (enExample)
CO (1) CO2017000571A2 (enExample)
DK (1) DK3171891T3 (enExample)
EA (1) EA039169B1 (enExample)
ES (1) ES3054696T3 (enExample)
FI (1) FI3171891T3 (enExample)
GB (1) GB201413240D0 (enExample)
HR (1) HRP20251560T1 (enExample)
IL (1) IL249981B (enExample)
LT (1) LT3171891T (enExample)
MX (1) MX2017001138A (enExample)
MY (1) MY196858A (enExample)
PL (1) PL3171891T3 (enExample)
PT (1) PT3171891T (enExample)
RS (1) RS67520B1 (enExample)
SG (1) SG11201700172WA (enExample)
SI (1) SI3171891T1 (enExample)
WO (1) WO2016012285A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
WO2017210360A1 (en) 2016-05-31 2017-12-07 Cardiovax, Llc Methods for diagnosing and treating systemic lupus erythematosus
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
CA3148826A1 (en) * 2019-08-01 2021-02-04 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
CA3149395A1 (en) * 2019-08-01 2021-02-04 Memorial Sloan-Kettering Cancer Center Cells for improved immunotherapy and uses thereof
EP4096691A1 (en) 2020-01-28 2022-12-07 Freeline Therapeutics Limited Improved assay for determining neutralising antibody titre to a viral vektor
GB202002072D0 (en) * 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
GB202003129D0 (en) * 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
GB202007434D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN120078887A (zh) * 2020-09-21 2025-06-03 上海宝济药业股份有限公司 一种药物组合及其应用
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
EP4433587A2 (en) 2021-11-15 2024-09-25 Hansa Biopharma AB Methods for enhancing adoptive cell transfer immunotherapies
IL315305A (en) 2022-03-17 2024-10-01 Astrazeneca Ireland Ltd Improved IgG-degrading enzymes and methods of using them
AU2023383441A1 (en) 2022-11-18 2025-06-05 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
CN116087528A (zh) * 2022-12-27 2023-05-09 华中科技大学同济医学院附属同济医院 一种sqtsm1蛋白在卵巢早衰的应用
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof
WO2025047848A1 (ja) 2023-08-30 2025-03-06 アステラス製薬株式会社 ＩｄｅＺ改変体
WO2025248469A1 (en) * 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. TREATMENT OF IgG-RELATED DISEASES
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
GB202413764D0 (en) 2024-09-18 2024-10-30 Genovis Ab Immunoglobulin proteases and their uses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
JPH0612624B2 (ja) * 1984-06-20 1994-02-16 株式会社日立製作所 半導体集積回路装置
US6006752A (en) * 1996-05-09 1999-12-28 The General Hospital Corporation Mixed chimerism and tolerance
CN105770871A (zh) * 2005-06-09 2016-07-20 汉莎医药有限公司 IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
GB2427360A (en) * 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
CN102584989B (zh) * 2007-09-14 2015-05-13 季诺维斯公司 用于解离Fcgamma-受体-IgG复合物及纯化与检测IgG的方法和试剂盒
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) * 2012-01-26 2012-03-07 Isis Innovation Composition
TWI626491B (zh) * 2012-12-10 2018-06-11 布萊恩荷登視覺協會 用於視力校正之具有一或多個多正焦區域之眼用光學透鏡
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods

Also Published As

Publication number Publication date
CN106714834A (zh) 2017-05-24
US20260000739A1 (en) 2026-01-01
JP6708641B2 (ja) 2020-06-10
EP3171891B1 (en) 2025-09-10
PL3171891T3 (pl) 2026-02-23
DK3171891T3 (da) 2025-12-15
US12397044B2 (en) 2025-08-26
EA039169B1 (ru) 2021-12-13
CA2955704A1 (en) 2016-01-28
ES3054696T3 (en) 2026-02-05
HK1232122A1 (en) 2018-01-05
PT3171891T (pt) 2025-11-25
EP4663755A2 (en) 2025-12-17
RS67520B1 (sr) 2025-12-31
EA201790192A1 (ru) 2017-09-29
US20210260173A1 (en) 2021-08-26
KR20230119267A (ko) 2023-08-16
HRP20251560T1 (hr) 2026-01-16
AU2015294125A1 (en) 2017-02-02
US20170209550A1 (en) 2017-07-27
WO2016012285A3 (en) 2016-04-14
KR20170039243A (ko) 2017-04-10
EP4663755A3 (en) 2026-04-15
CL2017000191A1 (es) 2017-08-25
AU2015294125B2 (en) 2020-10-15
MY196858A (en) 2023-05-05
LT3171891T (lt) 2025-12-29
JP2017522384A (ja) 2017-08-10
SI3171891T1 (sl) 2026-01-30
CN114949187A (zh) 2022-08-30
EP3171891A2 (en) 2017-05-31
US10973889B2 (en) 2021-04-13
CO2017000571A2 (es) 2017-06-20
WO2016012285A2 (en) 2016-01-28
MX2017001138A (es) 2017-06-07
FI3171891T3 (fi) 2025-12-08
SG11201700172WA (en) 2017-02-27
NZ728265A (en) 2024-03-22
IL249981A0 (en) 2017-03-30
KR102565244B1 (ko) 2023-08-10
IL249981B (en) 2022-08-01
BR112017001420A2 (pt) 2017-11-28

Similar Documents

Publication Publication Date Title
GB201417712D0 (en) Method
SG11201700172WA (en) Method
GB201406151D0 (en) Method
GB201409558D0 (en) Method
GB201418159D0 (en) Method
GB201414496D0 (en) Method
GB201408119D0 (en) Method
GB201417042D0 (en) Method
GB201410101D0 (en) Method
GB201412802D0 (en) Method
GB201411500D0 (en) Method
GB201416849D0 (en) Method
GB201416675D0 (en) Method
GB201409234D0 (en) Method
GB201409128D0 (en) Method
GB201414181D0 (en) Method
GB201412736D0 (en) Method
GB201412226D0 (en) Method
GB201409101D0 (en) Method
GB201413929D0 (en) Method
GB201413612D0 (en) Method
GB201408649D0 (en) Method
GB201407971D0 (en) Method
GB201418459D0 (en) Method
GB201416908D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)